#China #Suzhou #cancer therapy #TYVYT® #ELUNATE®

Groundbreaking Approval for Advanced Endometrial Cancer Treatment

Innovent Biologics, Inc. and HUTCHMED (China) Limited have made a significant announcement regarding cancer treatment innovation. Recently, they jointly revealed that the New Drug Application (NDA) for combining TYVYT® (sintilimab injection) with ELUNATE® (fruquintinib) has received conditional approval from the National Medical Products Administration (NMPA) in China. This dual therapy targets advanced endometrial cancer in patients who have previously undergone systemic therapy and are not suitable for curative surgery or radiation.

Contextual Background

This advancement marks an essential milestone, following the priority review status granted by the NMPA and the designation of breakthrough therapy. The approval comes as the eighth indication for TYVYT®, a symbol of its growing role in the oncology landscape.

Study Insights

Data supporting this conditionally approved therapy emerged from the FRUSICA-1 study, a multi-center, open-label Phase 2 clinical trial. The results, which were highlighted at the American Society of Clinical Oncology annual meeting in June 2024, indicated encouraging outcomes for patients with recurrent or resistant endometrial cancer.

The trial demonstrated an Overall Response Rate (ORR) of 35.6% and a Disease Control Rate (DCR) of 88.5% when sintilimab was paired with fruquintinib. Impressively, patients experienced a median Time to Tumor Response (mTTR) of just 1.6 months.

The Impact of Approval

Prof. Xiaohua Wu, the Director of Gynecologic Oncology at Fudan University, emphasized the significance of this combination treatment. He noted that it could revolutionize the management of about 417,000 new cases of endometrial cancer diagnosed worldwide in 2020 alone, with 97,000 fatalities stemming from the disease.

With limited existing options for patients with advanced stages of this cancer, the timely approval of sintilimab and fruquintinib provides a hopeful avenue for improved treatments and outcomes.

Commitment to Patients

Dr. Hui Zhou, Seniors Vice President at Innovent, expressed their collective hope that this treatment could meaningfully enhance survival rates and quality of life for patients battling this aggressive form of cancer. The synergy observed between immunotherapy and targeted treatment offers a much-needed solution for individuals who have not responded well to traditional therapy options.

Dr. Michael Shi, Head of Research and Development at HUTCHMED, mirrored these sentiments, emphasizing the need for effective treatment pathways and the potential of using fruquintinib in conjunction with other therapeutic agents.

Need for Continued Research

Despite the promising results, the collaborative teams understand the necessity for continued exploration. A Phase 3 confirmatory trial of this innovative combination therapy is on the horizon, indicating ongoing efforts to solidify the benefits and establish new standards in endometrial cancer treatment.

Conclusion

As Innovent and HUTCHMED target the delivery of this combination therapy, they align their missions with a larger goal: enhancing the quality of life for patients and addressing critical gaps in cancer care. The journey ahead is filled with potential, as both companies navigate through innovations that aim to transform therapeutic landscapes for various cancers.

About the Companies

Innovent is dedicated to developing high-quality biopharmaceuticals for major diseases, while HUTCHMED focuses on targeted therapies and immunotherapy for cancer. Their joint effort heralds a new era in oncology, one marked by innovative treatments and promising patient outcomes.

For further information on clinical studies, you may visit clinicaltrials.gov using identifier NCT03903705.

• ---

In conclusion, as the healthcare landscape continues to evolve, collaborations between biopharmaceutical companies and advancements in clinical trials remain pivotal. This recent news ushers in optimism for individuals grappling with advanced endometrial cancer, emphasizing the power of innovation in medical science to create viable solutions for unmet medical needs.